Ripollone JE, Huybrechts KF, Rothman KJ, Ferguson RE, Franklin JM. Evaluating the utility of coarsened exact matching for pharmacoepidemiology using real and simulated claims data. Am J Epidemiol. 2019 Dec 17. doi: 10.1093/aje/kwz268
Garcia-Albeniz X, Hsu J, Bretthauer M, Hernan MA. Estimating the effect of preventive services with databases of administrative claims: reasons to be concerned. Am J Epidemiol. 2019 Oct;188(10):1764-7. doi: 10.1093/aje/kwz049
Millar M, Kinney AY, Camp N, Cannon-Albright L, Hashibe M, Penson D, Kirchhoff A, Neklason D, Gilsenan A, Dieck GS, Stroup AM, Edwards SL, Bateman C, Carter ME, Sweeney C. Predictors of response outcomes for research recruitment through a central cancer registry: evidence from 17 population-based studies. Am J Epidemiol. 2019 May 1;188(5):928-39. doi: 10.1093/aje/kwz011
Trantham L, Sikirica MV, Candrilli S, Benson VS, Mohan D, Neil D, Joshi AV. Healthcare costs and utilization associated with muscle weakness diagnosis codes in patients with chronic obstructive pulmonary disease: a United States claims analysis. J Med Econ. 2019 Apr;22(4):319-27. doi: 10.1080/13696998.2018.1563414.
Sturmer T, Rothman KJ, Avorn J, Glynn RJ. Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution—A simulation study. Am J Epidemiol. 2010 Oct 17;172(7):843-54.
Mauskopf JA, Baker CL, Monz BU, Juniper MD. Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidence. J Med Econ. 2010 Sep 1;13(3):403-17.
Woodward TC, Brown R, Sacco P, Zhang J. Budget impact model of tobramycin inhalation solution for treatment of pseudomonas aeruginosa in cystic fibrosis patients. J Med Econ. 2010;13(3):492-9. doi: 10.3111/13696998.2010.505863